CD34 and hemophilia A: In terms of HSPC LV-fVIII design and preclinical testing, we published a comprehensive set of preclinical studies supporting the clinical testing of an HSPC gene therapy for hemophilia A. The product candidate, referred to as CD68-ET3-LV CD34+, consists of autologous CD34+ cells transduced with a HIV-1-based, monocyte lineage-restricted, self-inactivating LV encoding the high-expression ET3 transgene (Figure 4) (19, 24).